OctoPlus wins drug development and manufacturing contract from Danish pharmaceutical company
OctoPlus N.V. announced that a process development and manufacturing contract has been signed with a pharmaceutical company headquartered in Denmark. The undisclosed contract value will make a material contribution to OctoPlus' annual revenues.
Under the contract terms, OctoPlus will perform process development and manufacturing of a microsphere-based formulation for our client.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.